Tianjin Pharmaceutical Da Ren Tang Group Corporation Stock Forecast for 2023 - 2025 - 2030

Updated on 03/29/2024

Stock Rating
18
Price Target
$44.28
Consensus
Outperform
Upside
48.94%
Analysts
0
Stock Rating
18
Upside
48.94%
Analysts
0
Price Target
$44.28

Tianjin Pharmaceutical Da Ren Tang Group Corporation Stock Forecast and Price Target

The average price target for Tianjin Pharmaceutical Da Ren Tang Group Corporation's stock set by recognized analysts recently is $44.28, which would result in a potential upside of approximately 48.94% if it reached this mark. The estimation is based on a high estimate of $44.28 and a low estimate of $44.28. Even if you are not interested in T14 stock, you should still be aware of its competitors.

$44.28

48.94% Upside

Buy
Buy

Tianjin Pharmaceutical Da Ren Tang Group Corporation Fair Value Forecast for 2023 - 2025 - 2030

In the last zero years, Tianjin Pharmaceutical Da Ren Tang Group Corporation's Price has increased by 100.00%, going from $0.00 to $0.00. In the next year, analysts are expecting an increase in Fair Value, predicting it will reach $26.25 – an increase of 100.00%. The Tianjin Pharmaceutical Da Ren Tang Group Corporation forecast is for Fair Value to reach $22.24 or grow by 100.00%.

2024 Fair Value Forecast
$26.25
2025 Fair Value Forecast
$32.25
2026 Fair Value Forecast
$17.50
2027 Fair Value Forecast
$15.50
2028 Fair Value Forecast
$19.56
2029 Fair Value Forecast
$24.54
2030 Fair Value Forecast
$22.24
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
600276 Stock Forecast Jiangsu Hengrui Medicine Buy 15
¥43.60 Buy/Sell ¥56.49 23.85%
600436 Stock Forecast Zhangzhou Pientzehuang Pharmac... Outperform 18
¥229.63 Buy/Sell ¥302.86 36.49%
000538 Stock Forecast Yunnan Baiyao Group Co.,Ltd Outperform 18
¥51.56 Buy/Sell ¥65.39 26.45%
1093 Stock Forecast CSPC Pharmaceutical Group Outperform 18
HK$6.01 Buy/Sell HK$9.50 54.24%
600085 Stock Forecast Beijing Tongrentang Outperform 16
¥43.10 Buy/Sell ¥61.18 50.81%

Tianjin Pharmaceutical Da Ren Tang Group Corporation Revenue Forecast for 2023 - 2025 - 2030

In the last two years, Tianjin Pharmaceutical Da Ren Tang Group Corporation's Revenue has increased by 24.92%, going from $6.60B to $8.25B. In the next year, analysts are expecting an increase in Revenue, predicting it will reach $10.25B – an increase of 24.21%. The Tianjin Pharmaceutical Da Ren Tang Group Corporation forecast is for Revenue to reach $10.18B or grow by 23.35%.

2024 Rev Forecast
$10.25B
2025 Rev Forecast
$11.63B
2026 Rev Forecast
$9.78B
2027 Rev Forecast
$9.37B
2028 Rev Forecast
$9.73B
2029 Rev Forecast
$10.36B
2030 Rev Forecast
$10.18B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
600196 Stock Forecast Shanghai Fosun Pharmaceutical ... Outperform 16
¥24.76 Buy/Sell ¥33.57 25.77%
000999 Stock Forecast China Resources Sanjiu Medical... Buy 18
¥54.57 Buy/Sell ¥65.95 15.43%
600079 Stock Forecast Humanwell Healthcare (Group) Buy 0
¥20.56 Buy/Sell ¥32.49 -34.29%

Tianjin Pharmaceutical Da Ren Tang Group Corporation Dividend per Share Forecast for 2023 - 2025 - 2030

In the last two years, Tianjin Pharmaceutical Da Ren Tang Group Corporation's Dividend per Share has grown, increasing from $0.30 to $1.12 – an increase of 273.33%. According to 2 prominent analysts, Tianjin Pharmaceutical Da Ren Tang Group Corporation's Dividend per Share will fall by 69.64% in the next year, reaching $0.34. By 2030, professionals believe that Tianjin Pharmaceutical Da Ren Tang Group Corporation's Dividend per Share will decrease by 39.65%, reaching $0.68 – a concerning trend for the company.

2024 DPS Forecast
$0.34
2025 DPS Forecast
$0.42
2026 DPS Forecast
$0.64
2027 DPS Forecast
$1.01
2028 DPS Forecast
$0.71
2029 DPS Forecast
$0.64
2030 DPS Forecast
$0.68
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
002294 Stock Forecast Shenzhen Salubris Pharmaceutic... Buy 18
¥27.78 Buy/Sell ¥35.65 33.19%
300146 Stock Forecast Byhealth Buy 15
¥16.96 Buy/Sell ¥26.39 41.51%
000513 Stock Forecast Livzon Pharmaceutical Group Outperform 18
¥36.98 Buy/Sell ¥39.23 11.41%

Tianjin Pharmaceutical Da Ren Tang Group Corporation Free Cash Flow Forecast for 2023 - 2025 - 2030

Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
600518 Stock Forecast Kangmei Pharmaceutical - 6
¥1.90 Buy/Sell ¥25.97 -100.00%
002262 Stock Forecast Jiangsu Nhwa Pharmaceutical Co... Buy 18
¥23.17 Buy/Sell ¥31.34 33.79%
600380 Stock Forecast Joincare Pharmaceutical Group ... Buy 18
¥11.61 Buy/Sell ¥14.72 26.79%

Tianjin Pharmaceutical Da Ren Tang Group Corporation EBITDA Forecast for 2023 - 2025 - 2030

In the last two years, Tianjin Pharmaceutical Da Ren Tang Group Corporation's EBITDA has grown, increasing from $658.57M to $783.89M – a growth of 19.03%. The next year looks promising for Tianjin Pharmaceutical Da Ren Tang Group Corporation, with analysts predicting EBITDA of $1.33B – an increase of 69.35%. Over the next seven years, experts anticipate that Tianjin Pharmaceutical Da Ren Tang Group Corporation's EBITDA will grow at a rate of 68.74%.

2024 EBITDA Forecast
$1.33B
2025 EBITDA Forecast
$1.63B
2026 EBITDA Forecast
$1.25B
2027 EBITDA Forecast
$1.13B
2028 EBITDA Forecast
$1.21B
2029 EBITDA Forecast
$1.35B
2030 EBITDA Forecast
$1.32B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
900904 Stock Forecast Shanghai Shenqi Pharmaceutical... - 13
$6.46 Buy/Sell $0.00 -100.00%
600867 Stock Forecast Tonghua Dongbao Pharmaceutical Buy 18
¥10.11 Buy/Sell ¥14.25 48.17%
600062 Stock Forecast China Resources Double-Crane P... Buy 16
¥21.19 Buy/Sell ¥26.00 8.54%

Tianjin Pharmaceutical Da Ren Tang Group Corporation EBIT Forecast for 2023 - 2025 - 2030

In the last two years, Tianjin Pharmaceutical Da Ren Tang Group Corporation's EBIT has grown by 21.83%, from $551.04M to $671.32M. For the next year, analysts are expecting EBIT to reach $1.58B – an increase of 134.84%. Over the next seven years, experts predict that EBIT will grow by 122.65%.

2024 EBIT Forecast
$1.58B
2025 EBIT Forecast
$1.93B
2026 EBIT Forecast
$1.36B
2027 EBIT Forecast
$1.21B
2028 EBIT Forecast
$1.35B
2029 EBIT Forecast
$1.55B
2030 EBIT Forecast
$1.49B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
603858 Stock Forecast Shandong Buchang Pharmaceutica... - 18
¥16.85 Buy/Sell ¥0.00 -100.00%
000623 Stock Forecast Jilin Aodong Pharmaceutical Gr... Buy 16
¥15.28 Buy/Sell ¥0.00 48.36%
6826 Stock Forecast Shanghai Haohai Biological Tec... Outperform 18
HK$39.35 Buy/Sell HK$65.08 65.39%

Tianjin Pharmaceutical Da Ren Tang Group Corporation EPS Price Prediction Forecast for 2023 - 2025 - 2030

In the last zero years, Tianjin Pharmaceutical Da Ren Tang Group Corporation's EPS has increased by 100.00%, going from $0.00 to $0.00. In the next year, analysts are expecting an increase in EPS, predicting it will reach $1.75 – an increase of 100.00%. The Tianjin Pharmaceutical Da Ren Tang Group Corporation forecast is for EPS to reach $1.48 or grow by 100.00%.

2024 EPS Forecast
$1.75
2025 EPS Forecast
$2.15
2026 EPS Forecast
$1.17
2027 EPS Forecast
$1.03
2028 EPS Forecast
$1.30
2029 EPS Forecast
$1.64
2030 EPS Forecast
$1.48
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
600422 Stock Forecast KPC Pharmaceuticals,Inc Buy 18
¥19.32 Buy/Sell ¥28.00 44.93%
002773 Stock Forecast Chengdu Kanghong Pharmaceutica... Buy 11
¥17.32 Buy/Sell ¥24.00 -100.00%
600535 Stock Forecast Tasly Pharmaceutical Group Hold 18
¥15.89 Buy/Sell ¥0.00 -8.12%